On Singles Day this year, people not only hoarded daily necessities, bought cosmetics and clothes, but also made a record reservation for HPV vaccine. In the first 10 minutes of the market, the scheduled quantity of HPV vaccine has exceeded the sales volume of the whole day on the 11th of last year.

With the incidence of cervical cancer showing a younger trend, on November 15th, the Chengdu Health Commission, together with the Municipal Bureau of Education and the Municipal Bureau of Finance, officially issued the Chengdu Comprehensive Prevention and Control of Cervical Cancer HPV vaccination implementation Plan (2021 version). The proposal is as follows:

Starting from 2021, the city's HPV vaccination work for school-age girls (13-14 years old) will be launched to achieve full coverage in districts (cities) and counties. It is planned that by the end of 2025, the HPV vaccination rate for school-age girls will be more than 90%.

The program points out that parents (guardians) can choose between domestic / imported bivalent and imported tetravalent HPV vaccines.The vaccination subsidy of 600 yuan per person will be given by the financial fund.

In addition, Guangdong Province said it would start free HPV vaccination for school-age girls in the province in September 2022.Since 2020, free HPV vaccination has been carried out in Ordos, Inner Mongolia, Xiamen, Fujian, Jinan, Shandong and other places.

As the second highest incidence of cancer among Chinese women, the incidence of cervical cancer in China ranks second in the world, accounting for 28% of the total number of cases in the world. But this cancer is also the only type of cancer that can be prevented, and its "prescription" is the HPV vaccine. At present, there are three kinds of HPV vaccines on the market, namely bivalent, tetravalent and nine-valent vaccines, the scope of application is as follows.

The demand gap of HPV vaccine is more than 300 million, and the market is large.

The introduction of the HPV vaccine program has further opened the HPV vaccine market. Data show that women between the ages of 9 and 14 need to be vaccinated with two injections, the imported bivalent vaccine is about 600 yuan per dose, and the domestic Xinkening is priced at 329 yuan per dose. The market size of HPV vaccine in China will grow from 5.84 billion yuan in 2018 to 21.36 billion yuan in 2023.

For a long time, there has been a situation that it is difficult to get a single shot of HPV vaccine, and the demand gap is expected to exceed 300m people.In terms of imported vaccines in China, Zhifei is currently the exclusive agent of Merck & Co Inc tetravalent and nine-valent HPV vaccines, and GlaxoSmithKline PLC produces bivalent HPV vaccines. In terms of domestic vaccines, at present, domestic HPV vaccines are basically contracted by Watson Biology and Wantai Biology.

Zhifei has long monopolized the domestic four-and nine-price market, mainly making profits by acting Merck & Co Inc's vaccine products, of which four-and nine-price vaccines contribute 87% of the company's revenue.

Announced on the evening of May 23, 2018, the company received the nine-valent Human Papillomavirus Vaccine (Saccharomyces cerevisiae) "Biological Product batch issuance Certificate" issued by the State Food and Drug Administration. The nine-valent HPV vaccine has been issued a certificate, marking the first batch of nine-valent HPV vaccine can officially enter the market for sale.

In May last year, Xinkening, the HPV vaccine of HPV concept leader Wantai Bio, was officially sold on the market.The price is about 60% of the price of imported vaccines. Wantai Bivalent HPV Vaccine Project started in 2003, completed three phases of clinical application and listing in November 2017, and was approved by the State Drug Administration on December 30, 2019 and obtained drug registration approval.

On November 15, Wantai Biological Bulletin showed that the core advantage of the company's bivalent HPV vaccine is that it only needs two injections to achieve a good preventive effect between the ages of 9 and 14.As of October 31, the total number of bivalent vaccines issued has exceeded 8 million, and the production capacity has reached 30 million units per year in the second half of the year.No matter in terms of the scale of production or the scale of batch issuance, it is showing a trend of rapid growth.